title: Quantitative Changes in Pigment Epithelial Detachment Area and Volume Predict Retreatment in Polypoidal Choroidal Vasculopathy.
abstract: OBJECTIVE
  To determine if changes in pigment epithelial detachment (PED) area and volume predict retreatment in polypoidal choroidal vasculopathy (PCV).
  
  
  METHODS
  Retrospective case-control study.
  
  
  METHODS
  PCV patients on pro re nata (PRN) anti-vascular endothelial growth factor (VEGF) therapy with >1 year follow-up at an academic retina service were included. Monthly anti-VEGF injections were given until a dry macula was achieved, and treatment deferred. Retreatment indication was recurrence of intraretinal or subretinal fluid or new hemorrhage. PED area and volume changes between visits with a dry macula ("D") and immediate preceding visits ("D-1") were analyzed with an automated optical coherence tomography-based software. Univariate and multivariate analyses were conducted to determine associations between changes in PED parameters and retreatment need at immediate subsequent visits ("D+1").
  
  
  RESULTS
  Twenty-two PCV patients (mean age 69.6 years) were included. Of 46 visits D, 11 (23.9%) were followed by retreatment at D+1. An increase in PED area (>0.43 mm2) and volume (>0.0245 mm3) from D-1 to D was associated with 18.2 (95% CI, 3.7-125.6; P < .001) and 101.9 (95% CI, 9.5-14 308.0; P < .001) higher retreatment odds at D+1, respectively. These associations remained significant after multivariate analyses adjusting for baseline PED area or volume, greatest linear dimension, and type of anti-VEGF agent.
  
  
  CONCLUSIONS
  In PCV on PRN anti-VEGF therapy, increases in PED area and volume at one visit, despite achievement of a dry macula, are associated with retreatment at the next visit. Retreatment criteria relying on intraretinal or subretinal fluid or new hemorrhages may be expanded to include PED changes. Studies are needed to determine if using PED parameters in treatment decisions reduces recurrences.
authors.affiliation: Department of Ophthalmology, National University Health System, Singapore.
authors.forename: Errol W
authors.initials: EW
authors.lastname: Chan
authors.affiliation: Montreal Retina Institute, Montreal, Canada.
authors.forename: Mohab
authors.initials: M
authors.lastname: Eldeeb
authors.affiliation: Department of Ophthalmology, National University Health System, Singapore.
authors.forename: Gopal
authors.initials: G
authors.lastname: Lingam
authors.affiliation: CaMos Statistical Analyses Center, McGill University Health Centre Research Institute, Montreal, Canada.
authors.forename: Doneal
authors.initials: D
authors.lastname: Thomas
authors.affiliation: Department of Ophthalmology, National University Health System, Singapore.
authors.forename: Mayuri
authors.initials: M
authors.lastname: Bhargava
authors.affiliation: Department of Ophthalmology, National University Health System, Singapore. Electronic address: ophv5@nus.edu.sg.
authors.forename: Caroline K
authors.initials: CK
authors.lastname: Chee
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D002452:Cell Count; D002829:Choroid / Q000098:blood supply*; D020256:Choroidal Neovascularization / Q000150:complications / Q000175:diagnosis* / Q000628:therapy; D005260:Female; D005451:Fluorescein Angiography / Q000379:methods; D005500:Follow-Up Studies; D005654:Fundus Oculi; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D011127:Polyps / Q000150:complications / Q000175:diagnosis* / Q000628:therapy; D012163:Retinal Detachment / Q000188:drug therapy* / Q000209:etiology / Q000628:therapy; D055213:Retinal Pigment Epithelium / Q000473:pathology*; D019233:Retreatment; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence / Q000379:methods; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A